TORONTO, June 11, 2018 /CNW/ - Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) ("Xanthic", CSE: xTHC) is pleased to announce a strategic partnership with ABH Pharma Inc. ("ABH"), a leading FDA-registered and GMP-certified manufacturer of in-house branded and private label dietary supplements in the United States. Through its partnership with Xanthic, ABH will offer "Xanthic Powered" CBD-infused products to customers across its broad range of dietary supplements. These products will be sold by a variety of well-known brick-and-mortar retailers and e-commerce websites.
Using the same non-cannabis and non-hemp CBD that powers Xanthic CBD Water, ABH is able to offer CBD-infused dietary supplement products for sale alongside its non-CBD products to customers. ABH manufactures products under its own brand names as well as under private label brands. All products using the Xanthic CBD powder will bear the catchphrase "Powered by Xanthic Solubles". (See Xanthic press release dated May 29, 2018 for more detail on Xanthic CBD Water).
Frank Cantone, President of ABH, stated: "We are excited to remain on the forefront of the nutraceuticals industry with this development. The Xanthic partnership allows us to provide our customers with a competitive advantage, continuing to meet the evolving demands of consumers."
Tim Moore, CEO of Xanthic, commented: "Our partnership with ABH represents an important step for Xanthic. It allows us to introduce "Powered by Xanthic" CBD powder technology to a broader consumer audience across the United States. The ABH portfolio of state-of-art dietary supplements is a perfect partner for our technology."
About ABH Pharma
ABH is an industry leader in the U.S. in the realm of dietary supplement manufacturing. ABH offers full turn-key services from formulation to bottling and order fulfillment. ABH takes pride in helping its clients' dreams of owning a world class supplement brand come true. Mastering both custom formulations and their growing private label line, ABH has set the status quo high. www.abhpharma.com
Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis and cannabis-infused products. Using a proprietary process, Xanthic empowers its strategic partners to deliver superior cannabinoid solubility, improved bioavailability, accurate micro-dosing, and greater consistency versus competitive infused products. Through its investment in Xanthic Beverages, Xanthic has access to non-cannabis derived CBD-infused products that qualify for distribution outside of the cannabis dispensary network and into mainstream retail. www.xanthicbio.com
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. There is no assurance that the strategic partnership with ABH will successfully produce benefits for Xanthic. Although such forward-looking statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances, except as required pursuant to applicable securities laws.